decitabine and cedazuridine

{
  "id": "MLC-T-ONC-002321",
  "term": "decitabine and cedazuridine",
  "field": "Oncology and biomedicine",
  "definitions": [
    "A combination of two drugs used to treat adults with myelodysplastic syndromes, including chronic myelomonocytic leukemia. It is also being studied in the treatment of other types of cancer. Decitabine stops cells from making DNA, which may help keep cancer cells from growing and may kill them. Cedazuridine prevents the breakdown of decitabine in the body, which may allow more cancer cells to be killed. Decitabine and cedazuridine is a type of antimetabolite and a type of cytidine deaminase inhibitor. Also called Inqovi.",
    "An orally available fixed-dose combination agent containing cedazuridine, a cytidine deaminase (CDA) inhibitor, and the cytidine antimetabolite decitabine, with potential antineoplastic activity. Upon oral administration of tdecitabine and cedazuridine, cedazuridine binds to and inhibits CDA, an enzyme primarily found in the gastrointestinal (GI) tract and liver that catalyzes the deamination of cytidine and cytidine analogs. This prevents the breakdown of decitabine, increases its bioavailability and efficacy while decreasing GI toxicity due to the administration of lower doses of decitabine. Decitabine exerts its antineoplastic activity through the incorporation of its triphosphate form into DNA, which inhibits DNA methyltransferase and results in hypomethylation of DNA. This interferes with DNA replication and decreases tumor cell growth."
  ],
  "synonyms": [
    "Inqovi",
    "CDA inhibitor E7727/decitabine combination agent ASTX727",
    "C-DEC",
    "cedazuridine/decitabine combination agent ASTX727",
    "cedazuridine/decitabine tablet",
    "DEC-C"
  ],
  "references": [
    "NCI Dictionary of Cancer Terms",
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/decitabine-and-cedazuridine/"
}